Trial reportScientific reports2022
Head-to-head comparison of
Trial report in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Diagnostic efficacy of [BMC cancer · 2024Pooled it
- Head-to-head comparison ofEJNMMI research · 2026Article
- Clinical performance of [European journal of nuclear medicine and molecular imaging · 2026Article
- Retrospective analysis of [ 99m Tc]Tc-HYNIC-PSMA single photon emission computed tomography CT in patients with prostate cancer.Nuclear medicine communications · 2026Article
- The diagnostic value of whole-body HYNIC-PSMA 11 -Tc [Annals of nuclear medicine · 2025Article
- Preclinical Evaluation of a Novel PSMA-Targeted AgentTomography (Ann Arbor, Mich.) · 2025Article
- Metastasis lesion segmentation from bone scintigrams using encoder-decoder architecture model with multi-attention and multi-scale learning.Quantitative imaging in medicine and surgery · 2025Article
- [Frontiers in medicine · 2025Article
- Bone metastases from endocrine cancer: advances in diagnosis, treatment, and prevention.Frontiers in endocrinology · 2025Review
- Darolutamide-based triple therapy combined with PSMA imaging guided focal treatment in patients with prostate cancer: a multicenter retrospective study.Frontiers in pharmacology · 2025Article
- Imaging and therapy in prostate cancer using prostate specific membrane antigen radioligands.The British journal of radiology · 2024Review
- Quantitative vs. Qualitative SPECT-CT Diagnostic Accuracy in Bone Lesion Evaluation-A Review of the Literature.Diagnostics (Basel, Switzerland) · 2023Review
- Molecular imaging of bone metastasis.Journal of bone oncology · 2023Review
- Improving diagnostic efficacy of primary prostate cancer with combinedFrontiers in oncology · 2023Article
- Androgen deprivation therapy plus apalutamide as neoadjuvant therapy prior radical prostatectomy for patients with unresectable prostate cancer.Frontiers in pharmacology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The most common site of metastasis of prostate cancer (PCa) is bone. Skeletal-related events can increase the risk of death in patients with PCa by 28%. Due to the low detection rate of lesions in patients with low prostate-specific antigen (PSA) levels, the value of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.